Ok. I would like to explore this.
I think it is fair to presume no one can control the shareprice, but they can control what they say about the clinical evidence and what that means for risk of clinical failure and opportunity for a commercial drug.
I think everyone will prefer precise criticism, and we all have P2 data from the Sheba 2 combination study to refer to.
So...
Show me exactly what I said regarding FTO or the properties of Bisantrene as an FTO inhibitor when the SP was around $3 (basically Jan-Apr 2022) that did not correlate with effects seen in the Sheba 2 trial that we had an update for late 2023.
Why IMU is a multi multi bagger, page-24532
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |